(UroToday.com) In this presentation, Dr. Richard Cathomas summarized both abstracts LBA23 – (pembrolizumab combined with chemotherapy vs. chemotherapy alone as first-line therapy for advanced urothelial carcinoma: KEYNOTE-361), and abstract 697 – (phase 3, randomized, open-label study of the first-line durvalumab with or without tremelimumab vs. standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma [DANUBE]).